Compare · CTSO vs MMM
CTSO vs MMM
Side-by-side comparison of Cytosorbents Corporation (CTSO) and 3M Company (MMM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTSO and MMM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $92.51B, about 4143.0x CTSO ($22.3M).
- MMM has been more active in the news (5 items in the past 4 weeks vs 4 for CTSO).
- MMM has more recent analyst coverage (25 ratings vs 2 for CTSO).
- Company
- Cytosorbents Corporation
- 3M Company
- Price
- -
- -
- Market cap
- $22.3M
- $92.51B
- 1M return
- -7.20%
- -
- 1Y return
- -58.98%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 5
- Recent ratings
- 2
- 25
Cytosorbents Corporation
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintaining or improving the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a device to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Latest CTSO
- Cytosorbents Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
- Cytosorbents Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Cytosorbents Corporation
- CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights
- Cytosorbents Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
- SEC Form DEFA14A filed by Cytosorbents Corporation
- SEC Form DEF 14A filed by Cytosorbents Corporation
- Cytosorbents Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest MMM
- 3M Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation
- SEC Form 3 filed by new insider George Bobby K
- SEC Form 3 filed by new insider Cunningham Jennifer A.
- 3M Board Declares Quarterly Dividend
- Group President Chavez Rodriguez Beatriz Karina sold $663,430 worth of shares (3,635 units at $182.51), decreasing direct ownership by 21% to 14,035 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by 3M Company
- Sr Vice President & CAO Reinseth Theresa E sold $156,544 worth of shares (924 units at $169.42), decreasing direct ownership by 26% to 2,615 units (SEC Form 4)
- Executive Vice President Banovetz John Patrick exercised 7,880 shares at a strike of $154.69 and sold $1,343,067 worth of shares (7,880 units at $170.44) (SEC Form 4)
- EVP, Chief Legal Off & Secret Rhodes Kevin H exercised 7,669 shares at a strike of $154.69 and sold $1,312,933 worth of shares (7,669 units at $171.20) (SEC Form 4)
- Group President Goralski Christian T Jr exercised 4,902 shares at a strike of $154.69 and sold $835,577 worth of shares (4,902 units at $170.46), decreasing direct ownership by 0.00% to 6,971 units (SEC Form 4)